Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.69 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | GSK3A | P49840 | 3/20 | 0.61 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | INSR | P06213 | 2/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672242 | 0.84 | KDR (0.66) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL4671969 | 0.82 | KDR (1.00) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL14880012 | 0.79 | MEN1 (0.89) | BRAFMEN1KMT2ALMNATP53 | |
| SCHEMBL4670133 | 0.79 | KDR (1.00) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL4670094 | 0.78 | KDR (0.70) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL4670496 | 0.78 | KDR (1.00) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL4670122 | 0.77 | KDR (0.82) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL4672132 | 0.77 | KDR (0.84) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL14018421 | 0.76 | KDR (0.78) | KDRBRAFGSK3AGSK3BINSR | |
| SCHEMBL1121940 | 0.76 | BRAF (1.00) | KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330452-B1 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | ORTHO MCNEIL PHARM INC (US) | 2008-11-26 | — | — | EP | claimed |
| US-6710048-B2 | SELECTIVE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE; TO TREAT SOLID-TUMOR CANCERS, ANGIOGENESIS, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, ENDOMETRIOSIS AND PSORIASIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-03-23 | — | — | US | claimed |
| EP-1330452-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| US-20030060629-A1 | Pyrazine derivatives as modulators of tyrosine kinases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002024681-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| EP-1330452-B1 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | ORTHO MCNEIL PHARM INC (US) | 2008-11-26 | — | — | EP | disclosed |
| US-6710048-B2 | SELECTIVE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE; TO TREAT SOLID-TUMOR CANCERS, ANGIOGENESIS, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, ENDOMETRIOSIS AND PSORIASIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1330452-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030060629-A1 | Pyrazine derivatives as modulators of tyrosine kinases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002024681-A2 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060629-A1 | Pyrazine derivatives as modulators of tyrosine kinases | FLT1, FLT4, KDR | KDR 3/4885BRAF 5/4885GSK3A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.